Pharma News

What’s next for COVID dark horse Novavax?

This audio is auto-generated. Please let us know if you have feedback.

The early October FDA authorization of Novavax’s updated COVID-19 vaccine marked a much-needed win for the company. But the regulatory success hasn’t quieted concerns that surround Novavax’s position in the competitive landscape, such as the pace of its rollout, the company’s financial fortunes and the lackluster COVID-19 vaccine market.

Musaddiq Khan, vice president, digital clinical trials solutions in vaccines, Medable

Musaddiq Khan, vice president, digital clinical trials solutions in vaccines, Medable

Permission granted by Medable

 

A win is still a win, though, according to Musaddiq Khan, vice president of digital clinical trials solutions in vaccines at healthcare software company Medable.

“Some industry leaders have said this (authorization) was critical for the company’s financial success going forward, and yes, approval here was critical for Novavax as it’s the only product they can market at the moment,” Khan said.

Novavax reported a profit in the second quarter but has significantly scaled back its sales outlook for the year, anticipating vaccine sales of between $960 million to $1.14 billion as the focus remains on cost-cutting. The company plans to release more details that shed light on its post-approval standing in the coming weeks. 

“The company continues to make important progress against our goals, and you can expect to hear more about this during our Q3 earnings call,” Novavax officials said in an email to PharmaVoice.

A tried-and-true approach

The approved Novavax shot is an updated version of its original formulation, modified to target the Omicron XBB.1.5 variant. Unlike mRNA shots from Moderna and Pfizer-BioNTech, the jab uses a more traditional protein-based model employed by other common vaccines, including those for hepatitis B and shingles. This makes Novavax’s shot an alternative to mRNA or those ineligible for certain shots due to allergies or other factors.

Novavax’s own market research showed that 25% to 30% of people prefer a protein-based vaccine, a spokesperson said.

The vaccine, like the updated mRNA shots, was formulated for the XBB.1.5 variant, which is no longer the predominant circulating strain — that distinction goes to EG.5, otherwise known as Eris. However, experts believe that vaccines targeting the Omicron variant will still be effective against the newer crop of infections.

“The addition of a new protein-based vaccine is a helpful tool in the armory against COVID-19, and we need to be prepared for what the future could hold,” Khan said.

A few years ago, an FDA nod for a COVID-19 vaccine meant a significant windfall would soon follow. Now, however, dampened enthusiasm for COVID-19 vaccines and treatments has struck companies across the board. 

In mid-October, Pfizer, BioNTech, Moderna, and Novavax saw their stock prices drop after Pfizer scaled back a sales forecast by $9 billion for both its vaccine and COVID-19 treatment Paxlovid, citing softening interest in COVID-19 products. A recent poll found that less than half of adults (47%) plan to get an updated COVID-19 vaccine this fall, and 37% of previously vaccinated people said they will “probably” or “definitely” not opt to get the new one. 

“There has been a slump in demand for Covid-19 vaccinations, but Novavax brings a differentiator with its protein-based vaccine, a technology advantage that could alleviate any lingering public concerns around mRNA vaccines,” Kahan said.  

The road ahead

The latest approval didn’t come easy for Novavax — the company lost 95% of its market value since early 2022 and announced a restructuring this spring as sales of the original vaccine lagged. To shore up its financial position, Novavax sold 7% of its shares to South Korea’s SK Bioscience to reduce liabilities to the company.

Today, Novavax remains an underdog, competing against more established competitors with deeper pockets. About 7.6 million updated mRNA shots went into arms this fall before the FDA signed off on Novavax’s shot. Furthermore, the company is still awaiting approval by European Union regulators, who delayed their decision in mid-October after requesting more information from the company.

Source link
#Whats #COVID #dark #horse #Novavax

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *